Alnyam Pharmaceuticals (ALNY), which fell after reporting Q4 results last week, is down 4% AH...
Alnyam Pharmaceuticals (ALNY), which fell after reporting Q4 results last week, is down 4% AH after filing to sell 7M shares, worth $86.7M based on today's close. The company, less than a month removed from announcing a major restructuring plan, says it will use the proceeds to help advance its drug pipeline, including its ALN-TTR02 and ALN-APC drugs.
From other sites
at Zacks.com (Apr 9, 2015)
at Nasdaq.com (Mar 25, 2015)
at Zacks.com (Mar 13, 2015)
at Benzinga.com (Feb 27, 2015)
at Nasdaq.com (Jan 23, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs